Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Fischer, C; Leithner, K; Wohlkoenig, C; Quehenberger, F; Bertsch, A; Olschewski, A; Olschewski, H; Hrzenjak, A.
Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Mol Cancer. 2015; 14(8):4-4 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Fischer Carina
Hrzenjak Andelko
Leithner Katharina
Olschewski Andrea
Olschewski Horst
Quehenberger Franz
Wohlkönig Christoph
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 7
| | | | | | |
Abstract:
Lung cancer is one of the most frequent cancer types and the leading cause of cancer death worldwide. Cisplatin is a widely used chemotherapeutic for non-small cell lung carcinoma (NSCLC), however, its positive effects are diminished under hypoxia. We wanted to determine if co-treatment with cisplatin and histone deacetalyse (HDAC) inhibitor panobinostat can reduce hypoxia-induced cisplatin resistance in NSCLC cells, and to elucidate mechanism involved. Expression status of different HDACS was determined in two cell lines and in tumor tissue from 20 patients. Cells were treated with cisplatin, panobinostat, or with combination of both under normoxic and hypoxic (1% O(2)) conditions. Cell cycle, viability, acetylation of histones, and activation of apoptosis were determined. HIF-1α stability and its interaction with HDAC4 were analyzed. Most class I and II HDACs were expressed in NSCLC cells and tumor samples. Co-treatment of tumor cells with cisplatin and panobinostat decreased cell viability and increased apoptosis more efficiently than in primary, non-malignant bronchial epithelial cells. Co-treatment induced apoptosis by causing chromatin fragmentation, activation of caspases-3 and 7 and PARP cleavage. Toxic effects were more pronounced under hypoxic conditions. Co-treatment resulted in destabilization and degradation of HIF-1α and HDAC4, a protein responsible for acetylation and de/stabilization of HIF-1α. Direct interaction between HDAC4 and HIF-1α proteins in H23 cells was detected. Here we show that hypoxia-induced cisplatin resistance can be overcome by combining cisplatin with panobinostat, a potent HDAC inhibitor. These findings may contribute to the development of a new therapeutic strategy for NSCLC.
Find related publications in this database (using NLM MeSH Indexing)
Acetylation -
Anoxia - metabolism
Antineoplastic Agents - pharmacology
Apoptosis - drug effects
Carcinoma, Non-Small-Cell Lung - genetics
Cell Line, Tumor -
Cell Proliferation - drug effects
Cell Survival - drug effects
Cisplatin - pharmacology
DNA Fragmentation - drug effects
Drug Resistance, Neoplasm -
Drug Synergism -
Epithelial Cells - drug effects
Gene Expression -
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylases - genetics
Histones - metabolism
Humans -
Hydroxamic Acids - pharmacology
Hypoxia-Inducible Factor 1, alpha Subunit - metabolism
Indoles - pharmacology
Lung Neoplasms - genetics
Spheroids, Cellular - drug effects
Tumor Cells, Cultured -

Find related publications in this database (Keywords)
Non-small cell lung cancer
Cisplatin
Panobinostat
Apoptosis
HIF-1 alpha
© Meduni Graz Impressum